Heart failure mortality according to acute variations in N-terminal pro B-type natriuretic peptide and cystatin C levels

被引:12
|
作者
Carrasco-Sanchez, Francisco J. [1 ]
Perez-Calvo, Juan I. [2 ]
Morales-Rull, Jose L. [2 ]
Galisteo-Almeda, Luis [3 ]
Paez-Rubio, Inmaculada [1 ]
Baron-Franco, Bosco [1 ]
Aguayo-Canela, Mariano [1 ]
Pujol-De la llave, Emilio [1 ]
机构
[1] Hosp Juan Ramon Jimenez, Dept Internal Med, Huelva 21005, Spain
[2] Hosp Clin Univ Lozano Blesa, Dept Internal Med, Zaragoza, Spain
[3] Hosp Juan Ramon Jimenez, Dept Clin Chem & Lab Med, Huelva 21005, Spain
关键词
variations; mortality; cystatin C; heart failure; N-terminal pro B-type natriuretic peptide; prognosis; PROGNOSTIC VALUE; RENAL-FUNCTION; SERUM CREATININE; ADMISSION; OUTCOMES; TRIAL; METAANALYSIS; THERAPY; MARKERS; EVENTS;
D O I
10.2459/JCM.0b013e3283654bab
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim Changes in N-terminal pro B-type natriuretic peptide (NT-proBNP) levels and cystatin C (CysC) are predictors of adverse outcomes in acute heart failure. This study assess whether NT-proBNP variations might provide independent information in addition to that obtained from CysC levels. Methods NT-proBNP levels were assessed in patients admitted due to acute heart failure using an observational study. Patients were classified as follows: group 1, those with a decrease in NT-proBNP levels of at least 30% from admission to 4 weeks after discharge; group 2, those with no significant changes in levels; and group 3, those who showed an increase in NT-proBNP of 30%. A multivariable Cox regression model and c-statistics were used. The primary end-point was all-cause mortality at 1-year follow-up. Results A total of 195 patients completed the follow-up. The mortality rate reached 20.5% (40 patients); 14 out of the 32 in group 3. The cumulative incidence of death, according to the change in NT-proBNP and Kaplan-Meier analysis, showed a significant increase in group 3 (log-rank P = 0.004). In the multivariable analysis, NT-proBNP variation for group 3 (hazard ratio 4.27; P <0.001) and for group 2 (hazard ratio 2.19; P = 0.043) in comparison with group 1 were independently associated with all-cause mortality, as well as anemia, hyponatremia, and admission CysC levels. Patients in group 3, and those with levels of serum CysC above the median, were also associated with slight increase in mortality. Conclusion An increase of at least 30% in NT-proBNP levels after hospitalization is related to all-cause mortality in patients with acute heart failure and provides supplementary prognostic information in patients with high levels of CysC. A decrease in NT-proBNP of at least 30% is a desirable target to achieve.
引用
收藏
页码:115 / 121
页数:7
相关论文
共 50 条
  • [1] Prognostic value of serum cystatin C and N-terminal pro b-type natriuretic peptide in patients with acute heart failure
    Ignacio Perez-Calvo, Juan
    Jose Ruiz-Ruiz, Francisco
    Javier Carrasco-Sanchez, Francisco
    Luis Morales-Rull, Jose
    Manzano-Fernandez, Sergio
    Galisteo-Almeda, Luis
    Pascual-Figal, Domingo
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2012, 23 (07) : 599 - 603
  • [2] N-Terminal B-type Natriuretic Peptide in Heart Failure
    Richards, Arthur Mark
    HEART FAILURE CLINICS, 2018, 14 (01) : 27 - +
  • [3] B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are comparably useful for disease monitoring in heart failure
    Hammerer-Lercher, A
    Pölzl, G
    Falkensammer, G
    Ludwig, W
    Hügel, H
    Puschendorf, B
    Pachinger, O
    Mair, J
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2006, 106 (03) : 415 - 417
  • [4] Admission N-Terminal pro B-type natriuretic peptide levels predict multiple heart failure admissions
    Perez, Leandro
    Chiong, Jun
    JOURNAL OF CARDIAC FAILURE, 2008, 14 (06) : S112 - S113
  • [5] Differences of B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide levels in patients with cardiogenic shock
    Buerke, Michael
    Prondzinsky, Roland
    Geppert, Alexander
    Jaral, Rudolf
    Huber, Kurt
    Russ, Martin
    Lemm, Henning
    Schlitt, Axel
    Werdan, Karl
    CIRCULATION, 2007, 116 (16) : 944 - 944
  • [6] Clinical significance of the N-terminal pro-brain natriuretic peptide and B-type natriuretic peptide ratio in the acute phase of acute heart failure
    Sawatani, Tomofumi
    Shirakabe, Akihiro
    Okazaki, Hirotake
    Matsushita, Masato
    Shibata, Yusaku
    Shigihara, Shota
    Otsuka, Yusuke
    Kiuchi, Kazutaka
    Kobayashi, Nobuaki
    Hata, Noritake
    Shimizu, Wataru
    Asai, Kuniya
    EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE, 2021, 10 (09) : 1016 - 1026
  • [7] N-terminal pro-B-type natriuretic peptide levels in systolic heart failure
    Hamdi, I.
    Mahfoudhi, H.
    Ben Mansour, N.
    Mazni, F.
    Dahmani, R.
    Lahidheb, D.
    Fehri, W.
    Haouala, H.
    EUROPEAN JOURNAL OF HEART FAILURE, 2014, 16 : 79 - 79
  • [8] The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients
    O'Hanlon, Rory
    O'Shea, Paula
    Ledwidge, Mark
    O'Loughlin, Christina
    Lange, Sophie
    Conlon, Carmel
    Phelan, Dermot
    Cunningham, Sean
    Mcdonald, Ken
    JOURNAL OF CARDIAC FAILURE, 2007, 13 (01) : 50 - 55
  • [9] N-terminal pro-B-type natriuretic peptide in the diagnosis of acute heart failure
    Lee, K. K.
    Doudesis, D.
    Anwar, M.
    Astengo, F.
    Japp, A.
    Tsanas, A.
    Shah, A. S., V
    Januzzi, J. L.
    Mills, N. L.
    EUROPEAN HEART JOURNAL, 2020, 41 : 1210 - 1210
  • [10] Comparison of the cardiac markers B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide
    Buchner, Stefan
    Jungbauer, Carsten
    Birner, Christoph
    Debl, Kurt
    Riegger, Guenter A.
    Luchner, Andreas
    BIOMARKERS IN MEDICINE, 2009, 3 (05) : 465 - 481